Company intelligence / Profile preview
Ouro Medicines
San Francisco, California, USAouromedicines.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Lead asset OM336 is in Phase 2 trials for multiple myeloma in China with approximately 70 patients treated. The company is planning to launch a Phase 1 study in 2025 for immune-mediated diseases.
- Therapeutic areas
- OncologyRheumatologyImmunology
- Modalities
- T cell engagers (TCEs)bispecific antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GSKKeymed Biosciences (licensed OM336)
Beyond the preview
Go deeper on Ouro Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ouro Medicines.